MedTrace Logo

Safety Study of Erythropoietin (EPO) in Parkinson's Disease

NCT01010802 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-10-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is safe in the treatment of patients with Parkinson's Disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Erythropoietin human recombinant (EPOrh)

Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks

Sponsors & Collaborators

  • Centro de Immunologia Molecular, Cuba

    collaborator INDUSTRY

  • International Center for Neurological Restoration, Cuba

    lead OTHER

Principal Investigators

  • Ivonne Pedroso, M.D., M.Sc. · International Center for Neurological Restoration

  • Lazaro M Alvarez, M.D. · International Center for Neurological Restoration

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Cuba

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01010802 on ClinicalTrials.gov